Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592187 | 0.89 | ALDH1A1 (0.31) | ALDH1A1GAAUSP2MAPTCYP2C9 | |
| SCHEMBL7595344 | 0.86 | — | — | |
| SCHEMBL3475343 | 0.80 | ALDH1A1 (0.33) | ALDH1A1GAAMAPTCYP1A2KDM4E | |
| SCHEMBL7593790 | 0.79 | ALDH1A1 (0.35) | ALDH1A1GAAUSP2MAPTTDP1 | |
| SCHEMBL6162381 | 0.78 | ALDH1A1 (0.33) | ALDH1A1GAAUSP2MAPTTDP1 | |
| SCHEMBL7592041 | 0.74 | ALDH1A1 (0.42) | ALDH1A1GAACYP1A2KDM4ELMNA | |
| SCHEMBL10706815 | 0.73 | ALDH1A1 (0.31) | ALDH1A1GAAUSP2MAPTTDP1 | |
| SCHEMBL8162200 | 0.72 | ALDH1A1 (0.36) | ALDH1A1GAAUSP2MAPTTDP1 | |
| SCHEMBL6281752 | 0.72 | KDM4E (0.31) | KDM4E | |
| SCHEMBL24132476 | 0.71 | CYP1A2 (0.48) | ALDH1A1GAAUSP2MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8182785-B2 | Methods and compositions for generating singlet oxygen | NUTECH VENTURES (US) | 2012-05-22 | — | — | US | claimed |
| US-20100040530-A1 | Methods and Compositions for Generating Singlet Oxygen | NUTECH VENTURES | 2010-02-18 | — | — | US | claimed |
| US-8182785-B2 | Methods and compositions for generating singlet oxygen | NUTECH VENTURES (US) | 2012-05-22 | — | — | US | disclosed |
| US-8182785-B2 | Methods and compositions for generating singlet oxygen | NUTECH VENTURES (US) | 2012-05-22 | — | — | US | disclosed |
| EP-1496056-B1 | NOVEL COMPOUNDS AND ANTIMALARIALS | UNIV OKAYAMA (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20100040530-A1 | Methods and Compositions for Generating Singlet Oxygen | NUTECH VENTURES | 2010-02-18 | — | — | US | disclosed |
| US-20100040530-A1 | Methods and Compositions for Generating Singlet Oxygen | NUTECH VENTURES | 2010-02-18 | — | — | US | disclosed |
| US-7407984-B2 | Tetraoxaspriro anti-malarials | OKAYAMA UNIVERSITY (JP) | 2008-08-05 | — | — | US | disclosed |
| US-20050131058-A1 | Novel compounds and antimalarials | OKAYAMA UNIVERSITY (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-1496056-A1 | NOVEL COMPOUNDS AND ANTIMALARIALS | Okayama University (JP) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131058-A1 | Novel compounds and antimalarials | SQLE, NR1H3, ALOX15 | ALDH1A1 1705/4885GAA 3431/4885USP2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.